Effect of Organic Solvents on a Production of PLGA-Based Drug-Loaded Nanoparticles Using a Microfluidic Device

Overview

Journal ACS Omega

Publisher American Chemical Society

Specialty Chemistry

Date 2022 Sep 26

PMID 36157756

Authors

Yi Bao

Masatoshi Maeki

Akihiko Ishida

Hirofumi Tani

Manabu Tokeshi

Affiliations

Soon will be listed here.

Abstract

The translation of nanoparticles (NPs) from laboratory to clinical settings is limited, which is not ideal. One of the reasons for this is that we currently have limited ability to precisely regulate various physicochemical parameters of nanoparticles. This has made it difficult to rapidly perform targeted screening of drug preparation conditions. In this study, we attempted to broaden the range of preparation conditions for particle size-modulated poly(lactic--glycolic-acid) (PLGA) NP to enhance their applicability for drug delivery systems (DDS). This was done using a variety of organic solvents and a glass-based microfluidic device. Furthermore, we compared the PDMS-based microfluidic device to the glass-based microfluidic device in terms of the possibility of a wider range of preparation conditions, especially the effect of different solvents on the size of the PLGA NPs. PLGA NPs with different sizes (sub-200 nm) were successfully prepared, and three different types of taxanes were employed for encapsulation. The drug-loaded NPs showed size-dependent cytotoxicity in cellular assays, regardless of the taxane drug used.

Citing Articles

A Review of the Potential of Poly-(lactide-co-glycolide) Nanoparticles as a Delivery System for an Active Antimycobacterial Compound, 7-Methyljuglone.

Diedericks B, Kok A, Mandiwana V, Lall N Pharmaceutics. 2024; 16(2).

PMID: 38399270 PMC: 10893214. DOI: 10.3390/pharmaceutics16020216.

Biomaterials for Drug Delivery and Human Applications.

Trucillo P Materials (Basel). 2024; 17(2).

PMID: 38255624 PMC: 10817481. DOI: 10.3390/ma17020456.

Toward the Scalable, Rapid, Reproducible, and Cost-Effective Synthesis of Personalized Nanomedicines at the Point of Care.

Young H, He Y, Joo B, Ferguson S, Demko A, Butterfield S Nano Lett. 2024; 24(3):920-928.

PMID: 38207109 PMC: 11211002. DOI: 10.1021/acs.nanolett.3c04171.

Enhancing Therapeutic Efficacy against Infection in a Murine Model Using Rifampicin-Loaded PLGA Nanoparticles.

Hernandez-Giottonini K, Arellano-Reynoso B, Rodriguez-Cordova R, de la Vega-Olivas J, Diaz-Aparicio E, Lucero-Acuna A ACS Omega. 2024; 8(51):49362-49371.

PMID: 38162745 PMC: 10753543. DOI: 10.1021/acsomega.3c07892.

References

Chiu H, Samad N, Fang L, Lim V . Cytotoxicity of targeted PLGA nanoparticles: a systematic review. RSC Adv. 2022; 11(16):9433-9449. PMC: 8695459. DOI: 10.1039/d1ra00074h. View

Danhier F, Ansorena E, Silva J, Coco R, Le Breton A, Preat V . PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012; 161(2):505-22. DOI: 10.1016/j.jconrel.2012.01.043. View

Damiati S, Kompella U, Damiati S, Kodzius R . Microfluidic Devices for Drug Delivery Systems and Drug Screening. Genes (Basel). 2018; 9(2). PMC: 5852599. DOI: 10.3390/genes9020103. View

Bhardwaj V, Ankola D, Gupta S, Schneider M, Lehr C, Kumar M . PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res. 2009; 26(11):2495-503. DOI: 10.1007/s11095-009-9965-4. View

Xu A, Yao M, Xu G, Ying J, Ma W, Li B . A physical model for the size-dependent cellular uptake of nanoparticles modified with cationic surfactants. Int J Nanomedicine. 2012; 7:3547-54. PMC: 3405883. DOI: 10.2147/IJN.S32188. View

Lee J, Park C, Whitesides G . Solvent compatibility of poly(dimethylsiloxane)-based microfluidic devices. Anal Chem. 2003; 75(23):6544-54. DOI: 10.1021/ac0346712. View

Madani F, Esnaashari S, Mujokoro B, Dorkoosh F, Khosravani M, Adabi M . Investigation of Effective Parameters on Size of Paclitaxel Loaded PLGA Nanoparticles. Adv Pharm Bull. 2018; 8(1):77-84. PMC: 5896398. DOI: 10.15171/apb.2018.010. View

Kimura N, Maeki M, Sasaki K, Sato Y, Ishida A, Tani H . Three-dimensional, symmetrically assembled microfluidic device for lipid nanoparticle production. RSC Adv. 2022; 11(3):1430-1439. PMC: 8693528. DOI: 10.1039/d0ra08826a. View

Acharya S, Sahoo S . PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2010; 63(3):170-83. DOI: 10.1016/j.addr.2010.10.008. View

10.

Kumari A, Yadav S, Yadav S . Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2009; 75(1):1-18. DOI: 10.1016/j.colsurfb.2009.09.001. View

11.

Shah N, Chaudhari K, Dantuluri P, Murthy R, Das S . Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target. 2009; 17(7):533-42. DOI: 10.1080/10611860903046628. View

12.

Rhee M, Valencia P, Rodriguez M, Langer R, Farokhzad O, Karnik R . Synthesis of size-tunable polymeric nanoparticles enabled by 3D hydrodynamic flow focusing in single-layer microchannels. Adv Mater. 2011; 23(12):H79-83. PMC: 3123733. DOI: 10.1002/adma.201004333. View

13.

Maeki M, Uno S, Niwa A, Okada Y, Tokeshi M . Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J Control Release. 2022; 344:80-96. PMC: 8851889. DOI: 10.1016/j.jconrel.2022.02.017. View

14.

Dou M, Mireles Garcia Jr J, Zhan S, Li X . Interfacial nano-biosensing in microfluidic droplets for high-sensitivity detection of low-solubility molecules. Chem Commun (Camb). 2016; 52(17):3470-3. PMC: 4760840. DOI: 10.1039/c5cc09066k. View

15.

Legrand P, Lesieur S, Bochot A, Gref R, Raatjes W, Barratt G . Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation. Int J Pharm. 2007; 344(1-2):33-43. DOI: 10.1016/j.ijpharm.2007.05.054. View

16.

Paller C, Antonarakis E . Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011; 5:117-24. PMC: 3063116. DOI: 10.2147/DDDT.S13029. View

17.

Webb C, Khadke S, Schmidt S, Roces C, Forbes N, Berrie G . The Impact of Solvent Selection: Strategies to Guide the Manufacturing of Liposomes Using Microfluidics. Pharmaceutics. 2019; 11(12). PMC: 6955969. DOI: 10.3390/pharmaceutics11120653. View

18.

Wischke C, Schwendeman S . Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm. 2008; 364(2):298-327. DOI: 10.1016/j.ijpharm.2008.04.042. View

19.

Choi J, Cao J, Naeem M, Noh J, Hasan N, Choi H . Size-controlled biodegradable nanoparticles: preparation and size-dependent cellular uptake and tumor cell growth inhibition. Colloids Surf B Biointerfaces. 2014; 122:545-551. DOI: 10.1016/j.colsurfb.2014.07.030. View

20.

Busatto C, Pesoa J, Helbling I, Luna J, Estenoz D . Effect of particle size, polydispersity and polymer degradation on progesterone release from PLGA microparticles: Experimental and mathematical modeling. Int J Pharm. 2017; 536(1):360-369. DOI: 10.1016/j.ijpharm.2017.12.006. View